Anebulo doses >50% of subjects in Phase 2 trial for acute cannabinoid intoxication; expects IND by end of 2022

Anebulo Pharmaceuticals, Inc.

Dosed more than half of the 60 planned subjects in Part A of Phase 2 trial for ANEB-001 at CHDR in Netherlands.
Top-line data for Part A expected by end of H1 2022.
Plan to include Part A data in IND submission to FDA; expects to file IND before end of 2022.
CEO Simon Allen states robust enrollment enables smoother bridge to U.S. trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.